Zeidan et al. reported that the oral, more selective PLK1 inhibitor onvansertib with either low-dose cytarabine 20 mg/m2 on days 1 to 10 or decitabine 20 mg/m2 on days 1 to 5 in R/R AML was well tolerated in their phase 1b study [29]. This evidence concerns the gene PLK1 and acute myeloid leukemia.